
B/m/vinci8/data1/riedel/corpora/nyt/nyt/data/2006/10/12/1796674.xmló

TheDTO

drugsNNSO

mostRBSO

commonlyRBO

usedVBNO

toTOO

sootheVBO

	agitationNNO

andCCO


aggressionNNO

inINO

peopleNNSO

withINO

	AlzheimerNNPO

'sPOSO

diseaseNNO

areVBPO

noDTO

moreRBRO

	effectiveJJO

thanINO

placebosNNSO

forINO

mostJJSO

patientsNNSO
	
,,O

andCCO

putVBDO

themPRPO

atINO

riskNNO

ofINO

seriousJJO

sideNNO

effectsNNSO
	
,,O

	includingVBGO

	confusionNNO
	
,,O


sleepinessNNO

andCCO

	ParkinsonNNPORGANIZATION

'sPOSO

disease-likeJJO

symptomsNNSO
	
,,O

researchersNNSO

areVBPO

	reportingVBGO

todayNNO
	
..OEÇÄÄÄ¯ˇˇˇˇ&/guid/9202a8c04000641f80000000088fa136) )*ORGANIZATIONÑ

TheDTO

reportNNO
	
,,O

basedVBNO

onINO


aDTO

largeJJO


governmentNNO


comparisonNNO

ofINO

theDTO

drugsNNSO

'POSO

effectivenessNNO
	
,,O


challengesVBZO

currentJJO

practiceNNO

soRBO

sharplyRBO

thatINO

itPRPO

couldMDO

quicklyRBO

alterVBO

prescribingVBGO

habitsNNSO
	
,,O

someDTO

expertsNNSO

saidVBDO
	
..Oﬁ

AboutINO

4.5CDO

millionCDO

	AmericansNNPSO

sufferVBPO

fromINO

theDTO

progressiveJJO

dementiaNNO

ofINO

	AlzheimerNNPO

'sPOSO

diseaseNNO
	
,,O

andCCO

mostJJSO

patientsNNSO

withINO

theDTO

advancedJJO

diseaseNNO

exhibitNNO

	agitationNNO

orCCO

	delusionsNNSO

atINO

someDTO

pointNNO
	
..Oµ

TheDTO

drugsNNSO

testedVBDO

inINO

theDTO

studyNNO


--:O

ZyprexaNNPLOCATION

fromINO

EliNNPORGANIZATION

LillyNNPORGANIZATION
	
;:O

SeroquelNNPO

fromINO
 
AstraZenecaNNPORGANIZATION
	
;:O

andCCO

	RisperdalNNPLOCATION

fromINO

JanssenNNPLOCATION

PharmaceuticalNNPLOCATION


--:O

belongINO

toTOO


aDTO

classNNO

ofINO

medicationsNNSO

knownVBNO

asINO

atypicalJJO

antipsychoticsNNSO
	
..OáÄÄÄ¯ˇˇˇˇ *LOCATIONEÜÄÄÄ¯ˇˇˇˇ&/guid/9202a8c04000641f800000000071c2c0	 
*ORGANIZATIONEÖÄÄÄ¯ˇˇˇˇ&/guid/9202a8c04000641f8000000000247958 *ORGANIZATIONÑÄÄÄ¯ˇˇˇˇ *LOCATIONÉÄÄÄ¯ˇˇˇˇ *LOCATION¸

TheDTO

drugsNNSO

areVBPO

usedVBNO

toTOO

treatVBO

schizophreniaNNO

andCCO

otherJJO

	psychosesNNSO
	
,,O

andCCO

areVBPO

commonlyRBO


prescribedVBNO

forINO

elderlyJJO

patientsNNSO

inINO

	long-termJJO

careNNO


facilitiesNNSO
	
..OÔ

AboutINO


aDTO

thirdJJO

ofINO

theDTO

	estimatedVBNO

2.5CDO

millionCDO

MedicareNNPO

beneficiariesNNSO

inINO

nursingVBGO

homesNNSO

inINO

theDTO

UnitedNNPLOCATION

StatesNNPSLOCATION

haveVBPO

takenVBNO

theDTO

medicationsNNSO
	
,,O

researchersNNSO

foundVBDO
	
..OAàÄÄÄ¯ˇˇˇˇ&/guid/9202a8c04000641f80000000045917bf *LOCATION≥

AndCCO

theDTO

useNNO

ofINO

atypicalJJO

antipsychoticsNNSO

inINO

theDTO

elderlyJJO

accountsNNSO

forINO

anDTO

	estimatedVBNO
	
$$O


2CDO

billionCDO

inINO

theDTO

annualJJO

salesNNSO

ofINO

theDTO

drugsNNSO
	
,,O

muchRBO

ofINO

theDTO

costNNO

paidVBNO

byINO

MedicareNNPORGANIZATION

andCCO

MedicaidNNPO
	
..OâÄÄÄ¯ˇˇˇˇ *ORGANIZATIONê

	SpokesmenNNSO

forINO

LillyNNPORGANIZATION
	
,,O
 
AstraZenecaNNPORGANIZATION

andCCORGANIZATION

JohnsonNNPORGANIZATION

&CCORGANIZATION

JohnsonNNPORGANIZATION
	
,,O

whichWDTO

ownsVBZO

JanssenNNPPERSON
	
,,O

notedVBDO

thatINO

theDTO

drugsNNSO

wereVBDO

notRBO

approvedVBNO

byINO

theDTO

FoodNNPORGANIZATION

andCCORGANIZATION

DrugNNPORGANIZATION
#
AdministrationNNPORGANIZATION

forINO

useNNO

inINO

	AlzheimerNNPO

'sPOSO

patientsNNSO
	
,,O

andCCO

thatINO

theDTO

	companiesNNSO

didVBDO

notRBO

marketNNO

themPRPO

forINO

thatDTO

purposeNNO
	
..OEçÄÄÄ¯ˇˇˇˇ&/guid/9202a8c04000641f80000000000bec30 *ORGANIZATIONåÄÄÄ¯ˇˇˇˇ *ORGANIZATIONãÄÄÄ¯ˇˇˇˇ *PERSONEäÄÄÄ¯ˇˇˇˇ&/guid/9202a8c04000641f8000000000018a7c *ORGANIZATION∂

TheDTO

resultsNNSO

ofINO

theDTO

studyNNO
	
,,O

	publishedVBNO

todayNNO

inINO

TheDTO

NewNNPORGANIZATION

EnglandNNPORGANIZATION

JournalNNPORGANIZATION

ofINORGANIZATION

MedicineNNPORGANIZATION
	
,,O

simplyRBO

	reflectedVBDO

theDTO

needNNO

forINO

moreJJRO

researchNNO

intoINO

theDTO

	treatmentNNO

ofINO


behavioralJJO

problemsNNSO

inINO

	AlzheimerNNPO

'sPOSO

patientsNNSO
	
,,O

theDTO

	spokesmenNNSO

saidVBDO
	
..OéÄÄÄ¯ˇˇˇˇ
 *ORGANIZATIONß

PrescribingVBGO

informationNNO

forINO

theDTO

drugsNNSO

warnsVBZO

thatINO

patientsNNSO

withINO

	AlzheimerNNPO

'sPOSO
	
-:O

relatedVBNO

	psychosisNNO

''''O

areVBPO

atINO

	increasedVBNO

riskNNO

ofINO

deathNNO

comparedVBNO

toTOO

placeboVBO
	
..O

''''OÂ

ButCCO

theDTO

medicationsNNSO

areVBPO

commonlyRBO


prescribedVBNO

forINO

	AlzheimerNNPO

'sPOSO

patientsNNSO

''''O

offRPO

labelNNO

''''O

byINO

doctorsNNSO

becauseINO

familiesNNSO

areVBPO

	desperateJJO
	
,,O

becauseINO

theseDTO

drugsNNSO

	sometimesRBO

seemVBPO

toTOO

helpVBO
	
,,O

andCCO

becauseINO

company-sponsoredJJO

doctorsNNSO

promotedVBNO

themPRPO
	
..O

''''OÕ

TheDTO

questionNNO

isVBZO

whetherINO

theseDTO

drugsNNSO

haveVBPO


aDTO

placeNNO

inINO

theDTO

	treatmentNNO

ofINO

	AlzheimerNNPO

'sPOSO

patientsNNSO

atINO

allDTO
	
,,O

''''O

saidVBDO

Dr.NNPPERSON

JasonNNPPERSON

	KarlawishNNPPERSON
	
,,O

anDTO

	associateJJO

	professorNNO

ofINO

medicineNNO

atINO

theDTO


UniversityNNPORGANIZATION

ofINORGANIZATION
!
PennsylvaniaNNPORGANIZATION

whoWPO

wroteVBDO

anDTO

	editorialNNO

accompanyingVBGO

theDTO

studyNNO
	
..O

''''OêÄÄÄ¯ˇˇˇˇ *PERSONEèÄÄÄ¯ˇˇˇˇ&/guid/9202a8c04000641f800000000003e598  "*ORGANIZATIONÚ

IPRPO

thinkVBPO

theDTO

answerNNO

isVBZO

yesRBO
	
,,O

butCCO

onlyRBO

forINO


aDTO

subgroupNNO

ofINO

patientsNNSO

whoWPO

canMDO

tolerateVBO

themPRPO
	
,,O

andCCO

inINO


facilitiesNNSO

thatWDTO

haveVBPO

theDTO

	expertiseNNO

toTOO

manageVBO

theDTO

sideNNO

effectsNNSO
	
..O

''''O¥

InINO

theDTO

studyNNO
	
,,O

researchersNNSO

followedVBDO

421CDO

	AlzheimerNNPO

'sPOSO

patientsNNSO

withINO

	disablingJJO

	agitationNNO
	
,,O

	delusionsNNSO

orCCO

hallucinationsNNSO

whoWPO

wereVBDO

randomlyRBO

assignedVBNO

toTOO

receiveVBO

eitherDTO

dummyJJO

pillsNNSO

orCCO

oneCDO

ofINO

theDTO

threeCDO

antipsychoticJJO

drugsNNSO
	
..OÚ

DoctorsNNSO

adjustedVBNO

theDTO

dosesNNSO

asINO

neededVBNO
	
,,O

trackedVBDO

howWRBO

longJJO

theyPRPO

stayedVBDO

onINO

theDTO

drugsNNSO
	
,,O

andCCO

notedVBDO

theirPRP$O

improvementNNO
	
,,O

ifINO

anyDTO
	
..Oö

ExpertsNNSO

sayVBPO

thatINO

theDTO

amountNNO

ofINO

timeNNO


aDTO

patientNNO

spendsVBZO

onINO


aDTO


medicationNNO

isVBZO

anDTO

	importantJJO

measureNNO

ofINO

itsPRP$O


usefulnessNNO
	
,,O

becauseINO

patientsNNSO

oftenRBO

stopVBPO

takingVBGO


aDTO

drugNNO

ifINO

itPRPO

isVBZO

notRBO

doingVBGO

anyDTO

goodJJO

orCCO

ifINO

theDTO

sideNNO

effectsNNSO

areVBPO

intolerableJJO
	
..O°

AfterINO

12CDO

weeksNNSO
	
,,O

''''O

thereEXO

wereVBDO

noDTO

significantJJO

differencesNNSO

betweenINO

theDTO

groupsNNSO

withINO

regardNNO

toTOO

improvementNNO

''''O

onINO


aDTO

scaleNNO

thatINO

measuredJJO

symptomNNO

reliefNNO
	
,,O

saidVBDO

Dr.NNPPERSON

LonNNPPERSON

S.NNPPERSON

	SchneiderNNPPERSON
	
,,O

	professorNNO

ofINO


psychiatryNNO
	
,,O

	neurologyNNO

andCCO

gerontologyNNO

atINO

theDTO


UniversityNNPORGANIZATION

ofINORGANIZATION

SouthernNNPORGANIZATION


CaliforniaNNPORGANIZATION

SchoolNNPORGANIZATION

ofINORGANIZATION

MedicineNNPORGANIZATION
	
,,O

andCCO

theDTO

leadJJO

authorNNO

ofINO

theDTO

studyNNO
	
..OíÄÄÄ¯ˇˇˇˇ *PERSONëÄÄÄ¯ˇˇˇˇ) /*ORGANIZATIONı

TheDTO

researchersNNSO

alsoRBO

foundVBDO

noDTO

significantJJO


differenceNNO

inINO

theDTO

amountNNO

ofINO

timeNNO

theDTO

patientsNNSO

stayedVBDO

onINO

theDTO

drugsNNSO

orCCO

theDTO

placebosNNSO
	
;:O

aboutINO

80CDO

percentNNO

stoppedVBDO

takingVBGO

theDTO

drugsNNSO

andCCO

theDTO

placebosNNSO

alikeRBO

beforeINO

theDTO

endNNO

ofINO

theDTO

studyNNO
	
..OÒ

ButCCO

thoseDTO

onINO

theDTO

drugsNNSO

wereVBDO

farRBO

moreRBRO

likelyJJO

toTOO

quitVBO

becauseINO

ofINO

sideNNO

effectsNNSO
	
..O˜

TheDTO

sideNNO

effectsNNSO

includedVBDO

sedationNNO

inINO

15CDO

percentNNO

toTOO

24CDO

percentNNO

ofINO

theDTO

patientsNNSO
	
,,O

andCCO

	confusionNNO

inINO


6CDO

percentNNO

toTOO

18CDO

percentNNO
	
;:O

bothDTO

symptomsNNSO

canMDO

increaseVBO

theDTO

riskNNO

ofINO

fallsNNSO
	
..OÑ

AndCCO

12CDO

percentNNO

ofINO

theDTO

patientsNNSO

onINO

eitherDTO

ZyprexaNNPLOCATION

orCCO

	RisperdalNNPO

experiencedVBDO

	ParkinsonNNPO

'sPOSO
	
-:O

likeINO

symptomsNNSO
	
,,O

	includingVBGO

tremorsNNSO
	
..O

''''OìÄÄÄ¯ˇˇˇˇ *LOCATIONÒ

WhatWPO

theDTO

studyNNO

doesVBZO

indicateNNO

isVBZO

thatINO

thisDTO

isVBZO


aDTO

veryRBO

	sensitiveJJO


populationNNO

andCCO

thatINO

anyDTO

	treatmentNNO

needsVBZO

toTOO

beVBO

doneVBNO

withINO


aDTO

lotNNO

ofINO

forethoughtNNO

andCCO

constantJJO

reevaluationNNO

''''O

saidVBDO

Dr.NNPPERSON

BruceNNPPERSON

J.NNPPERSON

KinonNNPPERSON
	
,,O


aDTO

LillyNNPORGANIZATION

psychiatristNNO
	
..OïÄÄÄ¯ˇˇˇˇ "*PERSONEîÄÄÄ¯ˇˇˇˇ&/guid/9202a8c04000641f80000000000bec30% %*ORGANIZATIONà

Dr.NNPPERSON

ThomasNNPPERSON

R.NNPPERSON

InselNNPPERSON
	
,,O

directorNNO

ofINO

theDTO

NationalNNPORGANIZATION

	InstituteNNPORGANIZATION

ofINORGANIZATION

MentalNNPORGANIZATION

HealthNNPORGANIZATION
	
,,O

whichWDTO

financedVBDO

theDTO

researchNNO
	
,,O

saidVBDO
	
,,O

''''O

WhatWPO

thisDTO

studyNNO

showsVBZO

isVBZO

thatINO

theseDTO

drugsNNSO

areVBPO

clearlyRBO

notRBO

theDTO

answerNNO
	
;:O

theyPRPO

mayMDO

beVBO

helpfulJJO

forINO


aDTO

minorityNNO

ofINO

patientsNNSO

butCCO

wePRPO

needVBPO

toTOO

comeVBO

upRPO

withINO

betterJJRO

medicationsNNSO
	
..O

''''OóÄÄÄ¯ˇˇˇˇ  *PERSONEñÄÄÄ¯ˇˇˇˇ&/guid/9202a8c04000641f80000000002551ee *ORGANIZATION∏	

Dr.NNPPERSON

GaryNNPPERSON

KennedyNNPPERSON
	
,,O

directorNNO

ofINO

	geriatricJJO


psychiatryNNO

atINO


MontefioreNNPORGANIZATION

MedicalNNPORGANIZATION

CenterNNPORGANIZATION

inINO

theDTO

BronxNNPLOCATION
	
,,O

saidVBDO

thatINO

theDTO

resultsNNSO

gaveVBDO

psychiatristsNNSO

theDTO

firstJJO

clearJJO

pictureNNO

ofINO

whatWPO

manyJJO

hadVBDO

observedVBNO

inINO

theirPRP$O

	practicesNNSO
	
::O

thatDTO

improvementNNO

onINO

theDTO

drugsNNSO

isVBZO

usuallyRBO

modestJJO

atINO

bestJJSO
	
,,O

andCCO

thatDTO

behaviorNNO

andCCO

environmentNNO

areVBPO

oftenRBO

moreRBRO

	importantJJO

inINO

managingVBGO

	combativeJJO

	behaviorsNNSO
	
..O

''''OöÄÄÄ¯ˇˇˇˇ  *PERSONEôÄÄÄ¯ˇˇˇˇ&/guid/9202a8c04000641f8000000008e1ccce	 *ORGANIZATIONAòÄÄÄ¯ˇˇˇˇ&/guid/9202a8c04000641f80000000088fa9cf *LOCATIONà


OftentimesNNPO

theDTO

familyNNO

isVBZO

unwittinglyRBO

	provokingVBGO

theDTO

	agitationNNO
	
,,O

''''O

Dr.NNPPERSON

KennedyNNPPERSON

saidVBDO
	
..OõÄÄÄ¯ˇˇˇˇ
 *PERSON‡


ADTO

dementedJJO
	
,,O

confusedJJO

personNNO
	
,,O

hePRPO

notedVBDO
	
,,O

canMDO

becomeVBO

suddenlyRBO


aggressiveJJO

overINO

	seeminglyRBO

trivialJJO

thingsNNSO
	
,,O

likeINO


aDTO

changeNNO

inINO

dailyJJO

routineNNO

orCCO

feelingNNO

crowdedVBNO

orCCO

rushedVBNO
	
..O

''''OÎ

WorkingVBGO

onINO

theseDTO

kindsNNSO

ofINO


behavioralJJO

factorsNNSO

shouldMDO

alwaysRBO

beVBO

theDTO

firstJJO

lineNNO

ofINO

	treatmentNNO
	
,,O

''''O

Dr.NNPPERSON

KennedyNNPPERSON

saidVBDO
	
..OúÄÄÄ¯ˇˇˇˇ *PERSON®

TheDTO

reportNNO

isVBZO

theDTO

thirdJJO

largeJJO

studyNNO

inINO

theDTO

lastJJO

yearNNO

toTOO

concludeVBO

thatINO

atypicalJJO

antipsychoticsNNSO

areVBPO

notRBO

asINO

	effectiveJJO

orCCO

asRBO

safeJJO

asINO

	initiallyRBO

	portrayedVBNO
	
..OÏ

LastJJO

yearNNO
	
,,O


governmentNNO

researchersNNSO

foundVBDO

thatINO

threeCDO

ofINO

fourCDO

drugsNNSO

testedVBNO

wereVBDO

noDTO

moreRBRO

	effectiveJJO

thanINO

anDTO

olderJJRO
	
,,O

farRBO

lessRBRO

	expensiveJJO

drugNNO

inINO

treatingVBGO

schizophreniaNNO


--:O

theDTO

disorderNNO

forINO

whichWDTO

theDTO

medicationsNNSO

wereVBDO


originallyRBO

approvedVBNO
	
..OÏ

AndCCO

lastJJO

weekNNO
	
,,O

EnglishNNPO

researchersNNSO

	publishedVBDO


aDTO

studyNNO

thatWDTO

foundVBDO

thatINO

schizophreniaNNO

patientsNNSO

didVBDO

asRBO

wellRBO

onINO

olderJJRO

medicationsNNSO


--:O

orCCO

betterJJRO


--:O

thanINO

onINO

newerJJRO
	
,,O

atypicalJJO

drugsNNSO
	
..O